Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1070 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2024-05-11 (nature.com)
Chronic circadian rhythm disorder induces heart failure with preserved ejection fraction-like phenotype through the Clock-sGC-cGMP-PKG1 signaling pathway
Emerging evidence has documented that circadian rhythm disorders could be related to cardiovascular diseases. However, there is limited knowledge on the direct adverse effects of circadian misalignment on the heart. This study aimed to investigate the effect of chronic circadian rhythm disorder on
Read more
2024-03-11 (nature.com)
Ageing impairs the regenerative capacity of regulatory T cells in mouse central nervous system remyelination
Myelin regeneration (remyelination) is essential to prevent neurodegeneration in demyelinating diseases such as Multiple Sclerosis, however, its efficiency declines with age. Regulatory T cells (Treg) recently emerged as critical players in tissue regeneration, including remyelination. However, the effect of ageing on Treg-mediated regenerative processes is poorly understood. Here, we show that expansion of aged Treg does not rescue age-associated remyelination impairment due to an intrinsically diminished capacity of aged Treg to promote oligodendrocyte differentiation and myelination in male and female mice. This decline in regenerative Treg functions can be rescued by a young environment. We identified Melanoma Cell Adhesion Molecule 1 (MCAM1) and Integrin alpha 2 (ITGA2) as candidates of Treg-mediated oligodendrocyte differentiation that decrease with age.
Read more
2023-08-30 (endpts.com)
Charles River Laboratories to lay off 55 employees in California
Charles River Laboratories plans to lay off 55 employees in the Bay Area after deciding to stop its pharmacokinetic and pharmacology work there. According to a WARN notice in California, the layoffs will go into effect Sept. 19. A spokesperson for Charles River confirmed the layoffs.
Read more
2023-07-24 (globenewswire.com)
Investigation Alert CRL, FIS, GL, NSC: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Charles River Laboratories International, Inc. Johnson Fistel, LLP is investigating potential claims on...
Read more
2022-09-05 (ahajournals.org)
Mechanism of Eccentric Cardiomyocyte Hypertrophy Secondary to Severe Mitral Regurgitation
Background: Primary valvular heart disease is a prevalent cause of morbidity and mortality in both industrialized and developing countries. Although the primary consequence of valvular heart disease
Read more
2019-06-19 (nature.com)
Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment
Limitation of 5-fluorouracil (5-FU) anticancer efficacy is due to IL-1β secretion by myeloid-derived suppressor cells (MDSC), according to a previous pre-clinical report. Release of mature IL-1β is a consequence of 5-FU-mediated NLRP3 activation and subsequent caspase-1 activity in MDSC. IL-1β
Read more
2017-10-17 (nature.com)
Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function | Communications
Mesenchymal stromal cells (MSCs) are renoprotective and drive regeneration following injury, although cellular targets of such an effect are still ill-defined. Here, we show that human umbilical cord (UC)-MSCs transplanted into mice stimulate tubular cells to regain mitochondrial mass and function, associated with enhanced microtubule-rich projections that appear to mediate mitochondrial trafficking to create a reparative dialogue among adjacent tubular cells. Treatment with UC-MSCs in mice with cisplatin-induced acute kidney injury (AKI) regulates mitochondrial biogenesis in proximal tubuli by enhancing PGC1α expression, NAD+ biosynthesis and Sirtuin 3 (SIRT3) activity, thus fostering antioxidant defenses and ATP production. The functional role of SIRT3 in tubular recovery is highlighted by data that in SIRT3-deficient mice with AKI, UC-MSC treatment fails to induce renoprotection.
Read more
2004-09-14 (ahajournals.org)
Role of Interleukin-1β in Acute Inflammation and Graft Death After Cell Transplantation to the Heart
Background— Poor survival of grafted cells is a major factor hindering the therapeutic effect of cell transplantation; however, the causes of cell death remain unclear. We hypothesized that interleuk
Read more
(morningstar.com)
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids
Cell and gene therapies often rely on plasmid DNA (pDNA) as a critical starting material. However, production challenges such as capacity bottlenecks and timeline pressures, as well as a need for process development optimization can result in increased lead time, cost and complexity. Charles River’
Read more
(morningstar.com)
Charles River Laboratories Announces First-Quarter 2023 Results
Acquisitions contributed 1.8% to consolidated first-quarter revenue growth, and the divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 2.5%. The impact of foreign currency translation reduced reported revenue growth by 2.1%. Excluding the effect of these
Read more